) recently announced that the European Commission (EC) has
cleared its drug, Spedra, phosphodiesterase type 5 (PDE5)
inhibitor, for the treatment of erectile dysfunction (ED) in the
EU. The approval did not come as a surprise as, in Apr 2013, the
European Medicines Agency's (EMA) Committee for Medicinal
Products for Human Use (CHMP) recommended the approval of the
LILLY ELI & CO (LLY): Free Stock Analysis
PFIZER INC (PFE): Free Stock Analysis Report
SALIX PHARM-LTD (SLXP): Free Stock Analysis
VIVUS INC (VVUS): Free Stock Analysis Report
To read this article on Zacks.com click here.
The approval came on the basis of promising data from three phase
III trials REVIVE, REVIVE-Diabetes and REVIVE-RP and a year-long
safety study. Investors reacted positively to the news.
We note that the US Food and Drug Administration (FDA) approved
the drug under the trade name Stendra for ED in April last year.
VIVUS is looking for partners in the US and EU to market the
We note that a few days back VIVUS announced encouraging data
from a multi-center, placebo-controlled study (TA-501) evaluating
the efficacy of Stendra in men suffering from ED.
The study enrolled 440 patients with mild-to-severe ED with or
without diabetes. Data from the study revealed that on an average
Stendra was effective after 10 minutes and 12 minutes of taking
the 200 mg and 100 mg formulation of the drug, respectively.
According to the company, ED therapies recorded combined sales of
over $5.5 billion in 2012. The ED market is expected to grow
further in the coming years.
Currently approved PDE5 inhibitors including
) Viagra and
Eli Lilly and Company
) Cialis are recommended for ingestion one to two hours prior to
sexual activity or daily. We believe Stendra's fast action could
help the drug gain share once launched. Additionally, it will
also help VIVUS to secure a lucrative partnership deal for
Stendra in the US and EU.
VIVUS, currently carries a Zacks Rank #3 (Hold). Companies that
currently look attractive include
) with a Zacks Rank #1 (Strong Buy).